Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study
- PMID: 18045488
- PMCID: PMC2219993
- DOI: 10.1186/1471-230X-7-44
Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study
Abstract
Background: Peroxisome proliferators-activated receptor alpha (PPARalpha) activation modulates cholesterol metabolism and suppresses bile acid synthesis. This study aims to evaluate the effect of short-term administration of fenofibrate, a PPARalpha agonist, on proinflammatory cytokines, apoptosis, and hepatocellular damage in cholestasis.
Methods: Forty male Wistar rats were randomly divided into four groups: I = sham operated, II = bile duct ligation (BDL), III = BDL + vehicle (gum Arabic), IV = BDL + fenofibrate (100 mg/kg/day). All rats were sacrificed on 7th day after obtaining blood samples and liver tissue. Total bilirubin, aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP), gamma-glutamyl transferase, (GGT), tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1 beta), and total bile acid (TBA) in serum, and liver damage scores; portal inflammation, necrosis, bile duct number, in liver tissue were evaluated. Apoptosis in liver was also assessed by immunohistochemical staining.
Results: Fenofibrate administration significantly reduced serum total bilirubin, AST, ALT, ALP, and GGT, TNF-alpha, IL-1 beta levels, and TBA (P < 0.01). Hepatic portal inflammation, hepatic necrosis, number of the bile ducts and apoptosis in rats with BDL were more prominent than the sham-operated animals (P < 0.01). PPARalpha induction improved all histopathologic parameters (P < 0.01), except for the number of the bile duct, which was markedly increased by fenofibrate therapy (P < 0.01).
Conclusion: Short-term administration of fenofibrate to the BDL rats exerts beneficial effects on hepatocellular damage and apoptosis.
Figures


Similar articles
-
PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats.Turk J Gastroenterol. 2013;24(2):134-40. doi: 10.4318/tjg.2013.0605. Turk J Gastroenterol. 2013. PMID: 23934460
-
Decreased hepatic peroxisome proliferator-activated receptor-γ contributes to increased sensitivity to endotoxin in obstructive jaundice.World J Gastroenterol. 2011 Dec 28;17(48):5267-73. doi: 10.3748/wjg.v17.i48.5267. World J Gastroenterol. 2011. PMID: 22219595 Free PMC article.
-
Fenofibrate A peroxisome proliferator activated receptor-α agonist treatment ameliorates Concanavalin A-induced hepatitis in rats.Eur J Pharmacol. 2013 Dec 5;721(1-3):35-42. doi: 10.1016/j.ejphar.2013.09.058. Epub 2013 Oct 17. Eur J Pharmacol. 2013. PMID: 24140572
-
15-deoxy-delta 12,14-prostaglandin J2 prevents inflammatory response and endothelial cell damage in rats with acute obstructive cholangitis.Am J Physiol Gastrointest Liver Physiol. 2010 Mar;298(3):G410-8. doi: 10.1152/ajpgi.00233.2009. Epub 2010 Jan 7. Am J Physiol Gastrointest Liver Physiol. 2010. PMID: 20056897
-
Liposome Extract of Stachys pilifera Benth Effectively Improved Liver Damage due to Bile Duct Ligation Rats.Oxid Med Cell Longev. 2021 Oct 18;2021:8141563. doi: 10.1155/2021/8141563. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34707781 Free PMC article.
Cited by
-
β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor.Front Immunol. 2018 Jul 27;9:1735. doi: 10.3389/fimmu.2018.01735. eCollection 2018. Front Immunol. 2018. PMID: 30100908 Free PMC article.
-
Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity.Br J Pharmacol. 2019 Jul;176(13):2162-2178. doi: 10.1111/bph.14664. Epub 2019 May 7. Br J Pharmacol. 2019. PMID: 30875096 Free PMC article.
-
Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis.Inflammation. 2022 Dec;45(6):2570-2581. doi: 10.1007/s10753-022-01713-1. Epub 2022 Jul 15. Inflammation. 2022. PMID: 35838934 Free PMC article.
-
PPARα activation protects against cholestatic liver injury.Sci Rep. 2017 Aug 30;7(1):9967. doi: 10.1038/s41598-017-10524-6. Sci Rep. 2017. PMID: 28855630 Free PMC article.
-
Lipids in liver disease: looking beyond steatosis.Gastroenterology. 2012 Jan;142(1):8-11. doi: 10.1053/j.gastro.2011.11.004. Epub 2011 Nov 19. Gastroenterology. 2012. PMID: 22107717 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous